Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial-Reference-Cited by-同舟云学术

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

Published:2021-05 Issue:5 Volume:79 Page:665-673
ISSN:0302-2838
Container-title:European Urology
language:en
Short-container-title:European Urology

Author:

Powles Thomas,Atkins Michael B.^ORCID,Escudier Bernard,Motzer Robert J.,Rini Brian I.,Fong Lawrence,Joseph Richard W.,Pal Sumanta K.,Sznol Mario,Hainsworth John,Stadler Walter M.,Hutson Thomas E.,Ravaud Alain,Bracarda Sergio,Suarez Cristina,Choueiri Toni K.,Reeves James^ORCID,Cohn Allen,Ding Beiying,Leng Ning,Hashimoto Kenji,Huseni Mahrukh,Schiff Christina,McDermott David F.

Publisher

Elsevier BV

Subject

Urology

Reference18 articles.

1. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Kidney cancer. V2.2019.2018. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.

2. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Cancer Res,2012

3. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

4. Vascular normalization as an emerging strategy to enhance cancer immunotherapy;Huang;Cancer Res,2013

5. Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma;Wallin;Nat Commun,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the tumour vasculature: from vessel destruction to promotion;Nature Reviews Cancer;2024-08-29

2. Multi-cohort validation: A comprehensive exploration of prognostic marker in clear cell renal cell carcinoma;International Immunopharmacology;2024-06

3. A bibliometric analysis of the research landscape on vascular normalization in cancer;Heliyon;2024-04

4. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

5. Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review;Cancer Treatment Reviews;2024-01